<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We performed a Phase I/II study of the administration of recombinant human GM-CSF to patients suffering from severe <z:hpo ids='HP_0005528'>bone marrow failure</z:hpo>, either due to <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> or <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Doses ranging from 15 micrograms/m2 to 480 micrograms/m2 were administered as an intravenous infusion daily for 7 days </plain></SENT>
<SENT sid="2" pm="."><plain>Temporary improvements were seen in granulocyte counts, monocyte counts and reticulocyte counts </plain></SENT>
<SENT sid="3" pm="."><plain>There was no reduction in erythrocyte transfusion requirements and no effect was observed on platelet counts </plain></SENT>
<SENT sid="4" pm="."><plain>There was only minimal toxicity consisting of transient low back discomfort, <z:hpo ids='HP_0002039'>anorexia</z:hpo>, <z:hpo ids='HP_0003326'>myalgias</z:hpo>/<z:hpo ids='HP_0002829'>arthralgias</z:hpo>, and <z:hpo ids='HP_0011134'>low grade fever</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Our data suggest that prolonged use of GM-CSF might benefit some patients with severe marrow failure </plain></SENT>
</text></document>